Trials / Completed
CompletedNCT04651049
Systemic Propranolol for the Treatment of Paediatric Patients With Infantile Hemangiomas
Influence of Systemic Propranolol Treatment on the Physical Development of Paediatric Patients With Infantile Hemangiomas
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 128 (actual)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 2 Weeks – 54 Weeks
- Healthy volunteers
- Not accepted
Summary
This is retrospective study. The patients treated with oral propranolol at a dose of 2.0 mg/kg per day. Growth parameters (height and weight) were measured at the beginning, the end of treatment and 2 years after treatment. The weight-for-age Z-score (WAZ), height-for-age Z-score (HAZ) and weight-for-height Z-score (WHZ) calculated by the WHO Anthro software were used to assess physical development, and the WHO Child Growth Standards were used as the standards.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | propranolol | This retrospective study included 128 patients treated with oral propranolol at a dose of 2.0 mg/kg per day. |
| DEVICE | — |
Timeline
- Start date
- 2010-07-15
- Primary completion
- 2017-12-15
- Completion
- 2020-02-10
- First posted
- 2020-12-03
- Last updated
- 2020-12-03
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04651049. Inclusion in this directory is not an endorsement.